US Patent 11654153 Therapeutic treatment of breast cancer based on c-MAF status
Patent 11654153 was granted and assigned to Inbiomotion on May, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 9 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+22 properties)
Article (+461 characters)
US Patent 11654153 Therapeutic treatment of breast cancer based on c-MAF status
Article
The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
116541530
Date of Patent
May 23, 2023
0Patent Application Number
167660430
Date Filed
November 21, 2018
0Patent Citations
0
0
0
0
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11654153 Therapeutic treatment of breast cancer based on c-MAF status
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
